期刊文献+

常用生物标记物在脓毒症中的应用现状及展望 被引量:14

暂未订购
导出
摘要 全世界每年因脓毒症而死的人数是惊人的,且其发生率呈逐年递增,但脓毒症的疗效却没有得到明显提高[1]。脓毒症的发病机制复杂,仅通过患者症状和体征来进行诊断和分层是极其困难的,但脓毒症的早期诊断和分层对于及时或特异地给予治疗是十分重要的[2]。
出处 《实用医学杂志》 CAS 北大核心 2012年第4期662-663,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献16

  • 1Becker K L,Snider R,Nylen E S.Procalcitonin in sepsis and systemic inflammation:a harmful biomarker and a therapeutic target[J].Br J Pharmacol,2010,159(2):253-264.
  • 2Pierrakos C,Vincent J L.Sepsis biomarkers:a review[J].Crit Care,2010,14(1):R15.
  • 3Dellinqer R P,Levy M M,Carlet J M,et al.Surviving Sepsis Campaign:international guidelines for management of severe sepsis and septic shock:2008[J].Crit Care Med,2008,36(1):296-327.
  • 4Weiss M,Huber-Lang M,Taenzer M,et al.Different patient case mix by applying the 2003 SCCM/ESICM/ ACCP/ATS/SIS sepsis definitions instead of the 1992 ACCP/SCCM sepsis definitions in surgical patients:a retrospective observational study[J].BMC Med Inform Decis Mak,2009,9:25.
  • 5Schaub N,Frei R,Muller C.Addressing unmet clinical needs in the early diagnosis of sepsis[J].Swiss Med Wkly,2011,141:w13244.
  • 6Mueller C,Muller B,Perruchoud A P.Biomarkers:past,present,and future[J].Swiss Med Wkly,2008,138(15-16):225-229.
  • 7Bozza F A,Bozza P T,Castro Faria Neto HC.Beyond sepsis pathophysiology with cytokines:what is their value as biomarkers for disease severity[J]? Mem Inst Oswaldo Cruz,2005,100 (suppl 1):217-221.
  • 8Dahaba A A,Metzler H.Procalcitonin's role in the sepsis cascade.Is procalatitonin a sepsis marker or midiator[J]? Minerva Anestesiol,2009,75(7-8):447-452.
  • 9Celik I H,Demirel F G,Uras N,et al.What are the cut-off levels for IL-6 and CRP in neonatal sepsis[J]? Clin Lab Anal,2010,24(6):407-412.
  • 10Rey C,Los Arcos M,Concha A,et al.Procalcitonin and C-reactive protein as markers of systemic inflammatory response syndrome severity in critically ill children[J].Intensive Care Med,2007,33(3):477-484.

同被引文献161

引证文献14

二级引证文献95

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部